ARTELO BIOSCIENCES, INC. Marketable Securities, Unrealized Gain (Loss)
ARTELO BIOSCIENCES, INC. (ARTL) reported Marketable Securities, Unrealized Gain (Loss) of $2.14 thousand for the 6-month period ending 2021-02-28, per its 10-Q filed 2021-04-13.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2021-04-13
- 2021-02-28: Marketable Securities, Unrealized Gain (Loss) 6 month $2.14K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 6 month |
|---|---|
| 2021-02-28 | $2.14K 10-Q · filed 2021-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |